- GlucoTrack (GCTK) is expanding its product pipeline with the commencement of a new R&D program for a long-term continuous glucose monitor
- The company has also completed lab testing of its non-invasive GlucoTrack 2.0 clinical prototype system
- CEO Paul Goode sat down with Sabrina Cuthbert to discuss the R&D program and to expand on the company’s upcoming in-human trials
- GlucoTrack is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies
- GlucoTrack, Inc. (GCTK) opened trading at US$1.62
GlucoTrack (GCTK) is expanding its product pipeline with the commencement of a new R&D program for a long-term continuous glucose monitor.
Following the recent acquisition of certain related intellectual property, the company intends to develop a long-term implantable glucose management technology to address the growing Type 1 diabetes market.
Based on initial data, the company believes it can bring to market a solution that is more accurate, more convenient and has a significantly longer duration than current on-the-market solutions.
The company has also completed lab testing of its non-invasive GlucoTrack 2.0 clinical prototype system and observed better-than-expected accuracy and performance with the technology. The company is scheduled to begin its first-in-human trials later this quarter.
CEO Paul Goode sat down with Sabrina Cuthbert to discuss the R&D program and to expand on the company’s upcoming in-human trials.
“We are excited about entering into the Type 1 diabetes market, and we intend to continue to expand our line of product offerings to benefit all people with diabetes and prediabetes. We look forward to reporting our progress and are thankful to our shareholders who share our passion to pioneer new products for this monumental market.”
GlucoTrack is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with diabetes and prediabetes.
GlucoTrack, Inc. (GCTK) opened trading at US$1.62.
